title: Heart failure event definitions in drug trials in patients with type 2 diabetes.
authors.affiliation: Duke Clinical Research Institute, Duke University, Durham, NC, USA; Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, AB, Canada. Electronic address: a.sharma@dm.duke.edu.
authors.forename: Abhinav
authors.initials: A
authors.lastname: Sharma
authors.affiliation: Brigham and Women's Hospital Heart & Vascular Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
authors.forename: Deepak L
authors.initials: DL
authors.lastname: Bhatt
authors.affiliation: Hospital Clinic de Barcelona, Institut D'Investigacion Agusti Pi I Sunyer (IDIBAPS), Barcelona, Spain.
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Calvo
authors.affiliation: Vanderbilt University School of Medicine, Nashville, TN, USA.
authors.forename: Nancy J
authors.initials: NJ
authors.lastname: Brown
authors.affiliation: Hypertension and Preventive Cardiology Division, Department of Cardiovascular Disease, Centre d'Investigations Cliniques, Hopital Jeanne d'Arc, Nancy, France.
authors.forename: Faiez
authors.initials: F
authors.lastname: Zannad
authors.affiliation: Duke Clinical Research Institute, Duke University, Durham, NC, USA.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Mentz
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006333:Heart Failure / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D017410:Practice Guidelines as Topic / Q000592:standards*
chemical_list: D007004:Hypoglycemic Agents